This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gary W. Cole, MD; George Stricklin, MD, PhD

Arch Dermatol. 1989;125(11):1537-1539.

Abstract
• Fifty patients with tinea corporis were treated with either 500 mg of griseofulvin (microsize) or 500 mg of terbinafine daily for 6 weeks. Thirty-three patients completed the study. Thirteen (87%) of 15 patients who took terbinafine were considered successfully treated, while 13 (73%) of 18 patients in the griseofulvin group noted resolution of their disease. Five patients taking griseofulvin were forced to discontinue the therapy because of side effects, compared with two patients taking terbinafine. This preliminary study indicates that a new oral antifungal agent of the allylamine class, terbinafine, may possess a safety and efficacy profile similar to that of griseofulvin.

(Arch Dermatol. 1989;125:1537-1539)

Author Affiliations
From the Dermatology Service, Veterans Administration Medical Center, Long Beach, Calif (Dr Cole), and the Dermatology Section, Veterans Administration Medical Center, Nashville, Tenn (Dr Stricklin).

Footnotes
Accepted for publication June 7, 1989.

Reprint requests to Dermatology Service, Veterans Administration Medical Center, 5901 E Seventh St, Long Beach, CA 90822 (Dr Cole).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Terbinafine for the Treatment of Pedal Onychomycosis: A Foot Closer to the Promised Land of Cured Nails?
Shear and Gupta
Arch Dermatol 1995;131:937-942.
ABSTRACT